ProMIS Neurosciences is a clinical-stage biotechnology company committed to the discovery and development of therapeutic antibodies and vaccines selective for toxic oligomers associated with the development and progression of neurodegenerative and other misfolded protein diseases. The Company’s proprietary target discovery engine, EpiSelect, has been shown to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins that cause neurodegenerative and other misfolded protein diseases, including Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), multiple system atrophy (MSA), and Parkinson’s Disease (PD). ProMIS has offices in Cambridge, Massachusetts (USA) and Toronto, Ontario (CAN).Cash and cash equivalents were $15.4 million as of September 30, 2025, compared to $13.3 million as of December 31, 2024. The increase in cash was attributable to multiple transactions in July 2025, including a registered direct offering, private placements and discounted warrant exercises, where we received aggregate gross proceeds of approximately $21.6 million. Are biotech products safe for use ?
Previous Article
Palantir ValuationNext Article
Alternative browser for iOS users